Cel Sci Corporation (CVM)

[rwa3848]

Enrollment completion likely entailed a milestone payment to CRO, just as it entailed milestone stock awards. It is possible that the cost uncertainties presented by ARB, FDA, & SEC were the primary reason Cel-Sci tepidly attempted to alter Investigation protocols by using knowable death rate timelines as a pretext to delay contractually bound payment to CRO.